| Literature DB >> 4884653 |
M Mason, H L Currey, C G Barnes, J F Dunne, B L Hazleman, I D Strickland.
Abstract
The ability of azathioprine to reduce the corticosteroid requirements of patients with severe rheumatoid arthritis was tested under double-blind conditions against placebo. After 12 months a significant mean dose reduction of 36% was achieved without undue side-effects. This form of therapy promises to be an advance in the management of severe rheumatoid arthritis.Entities:
Mesh:
Substances:
Year: 1969 PMID: 4884653 PMCID: PMC1981902 DOI: 10.1136/bmj.1.5641.420
Source DB: PubMed Journal: Br Med J ISSN: 0007-1447